FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • February 28th, 2020 • Puma Biotechnology, Inc. • Pharmaceutical preparations
This First Amendment (the “First Amendment”), effective as of September 17, 2019 (“Effective Date of the First Amendment”), is made by and between Puma Biotechnology, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 10880 Wilshire Blvd, Los Angeles, CA 90024 (“Licensor”) and Pierre Fabre Medicament SAS, a company duly organized and existing under the laws of France, having offices and principal place of business at 45, Place Abel Gance 92100 Boulogne Billancourt, France (“Licensee”) (each individually a “Party” and collectively the “Parties”), and amends that certain License Agreement between the Parties effective as of March 29, 2019 (the “Agreement”). Capitalized terms used herein without definition shall have the meaning set forth in the Agreement.
SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • February 28th, 2020 • Puma Biotechnology, Inc. • Pharmaceutical preparations
This Second Amendment (the “Second Amendment”), effective as of November 25, 2019 (“Effective Date of the Second Amendment”), is made by and between Puma Biotechnology, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 10880 Wilshire Blvd, Los Angeles, CA 90024 (“Licensor”) and Pierre Fabre Medicament SAS, a company duly organized and existing under the laws of France, having offices and principal place of business at 45, Place Abel Gance 92100 Boulogne Billancourt, France (“Licensee”) (each individually a “Party” and collectively the “Parties”), and amends that certain License Agreement between the Parties effective as of March 29, 2019, amended by the First Amendment effective as of September 17, 2019 (together, the “Agreement”). Capitalized terms used herein without definition shall have the meaning set forth in the Agreement.
ContractNerlynx License Agreement • February 28th, 2020 • Puma Biotechnology, Inc. • Pharmaceutical preparations • New York
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
